Mesirow Financial Investment Management, Inc. Castle Biosciences Inc Transaction History

Mesirow Financial Investment Management, Inc.

$4.94 Billion
Q3 2024

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 12, 2023	BUY	$19.47 - $28.49 $280,971 - $411,139	14,431 New	14,431 $327,000
Q3 2022 Oct 26, 2022	BUY	$22.51 - $34.32 $179,337 - $273,427	7,967 New	7,967 $208,000
Q2 2022 Jul 20, 2022	SELL	$16.0 - $45.99 $127,760 - $367,230	-7,985 Closed	0 $0
Q1 2022 May 02, 2022	BUY	$33.17 - $46.98 $829 - $1,174	25 Added 0.31%	7,985 $358,000
Q3 2021 Oct 20, 2021	SELL	$60.13 - $77.6 $13,408 - $17,304	-223 Reduced 2.73%	7,960 $529,000
Q2 2021 Jul 23, 2021	BUY	$50.07 - $76.78 $1,702 - $2,610	34 Added 0.42%	8,183 $600,000
Q1 2021 Apr 14, 2021	SELL	$58.92 - $97.33 $11,666 - $19,271	-198 Reduced 2.37%	8,149 $558,000
Q4 2020 Jan 14, 2021	BUY	$43.6 - $73.05 $1,787 - $2,995	41 Added 0.49%	8,347 $560,000
Q3 2020 Oct 13, 2020	BUY	$38.47 - $52.03 $2,192 - $2,965	57 Added 0.69%	8,306 $427,000
Q2 2020 Jul 22, 2020	BUY	$27.28 - $43.01 $225,032 - $354,789	8,249 New	8,249 $311,000
Q1 2020 Apr 09, 2020	SELL	$23.08 - $35.53 $356,886 - $549,400	-15,463 Closed	0 $0
Q4 2019 Jan 09, 2020	BUY	$15.74 - $35.04 $243,387 - $541,823	15,463 New	15,463 $531,000

Others Institutions Holding CSTL

# of Institutions

202

Shares Held

26M

Call Options Held

303K

Put Options Held

30.3K

Black Rock Inc. New York, NY

3.04M
Shares

$85.6 Million
0.0% of portfolio
Wasatch Advisors Inc Salt Lake City, UT

1.83M
Shares

$51.3 Million
0.26% of portfolio
Vanguard Group Inc Valley Forge, PA

1.75M
Shares

$49.1 Million
0.0% of portfolio
Principal Financial Group Inc Des Moines, IA

1.54M
Shares

$43.2 Million
0.03% of portfolio
Bellevue Group Ag Kuesnacht, V8

1.26M
Shares

$35.5 Million
0.61% of portfolio

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $739M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mesirow Financial Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Mesirow Financial Investment Management, Inc. with notifications on news.

Account